We envision that the blocking pan‐RAF and S100B/p53 pathways might be a novel synergistic effect strategy for melanoma therapy and that complex 1 is an attractive scaffold for the further development of anti‐melanoma drugs targeting the pan‐RAF and S100B pathways. Here, RAF1 is linked to melanoma.